Featured Research

from universities, journals, and other organizations

Gene Therapy For Erectile Dysfunction Shows Promise In Clinical Trial

Date:
December 4, 2006
Source:
Albert Einstein College of Medicine
Summary:
The first human trial of gene transfer therapy for erectile dysfunction (ED) indicates that gene therapy that lasts for months and eliminates the patient's need for on-demand drugs (such as Viagra and Cialis), could become the future treatment of choice for this common problem, according to a paper in the most recent issue of Human Gene Therapy.

The first human trial of gene transfer therapy for erectile dysfunction (ED) indicates that gene therapy that lasts for months and eliminates the patient’s need for on-demand drugs (such as Viagra and Cialis), could become the future treatment of choice for this common problem, according to a paper in the most recent issue ofHuman Gene Therapy.

Related Articles


Lead author Arnold Melman, M.D., professor and chair of the Department of Urology at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center, says, “This is an exciting field of research because current treatments for men with erectile dysfunction, whether pills or minimally invasive therapies, must be used ‘on demand’, thereby reducing the spontaneity of the sexual act.”

Erectile dysfunction affects more than 50 percent of men aged 40 to70 and 70 percent above age 70, according to the Massachusetts Male Aging Study.

Dr. Melman and two study centers worked with 11 men and administered various doses of a transfer gene called hMaxi-K. “While this phase 1 safety trial was not designed to provide efficacy answers, one patient in each of the higher dose groups (5000 and 7500 micrograms) reported clinically significant and sustained improvements in ED. And, there have been no adverse effects with the patients in the study, so it has been proven to be safe,” he adds.

Because there has been widely publicized adverse results using viruses as agents to transfer genes into humans, Dr. Melman has chosen to transfer the hMaxi-K gene using “naked DNA,” a form of circular DNA which remains independent and does not integrate with chromosomal DNA in the muscle cells.

“The hMaxi-K stimulates potassium ion transfer in the smooth muscle cells of the penis,” says Dr. Melman. The hMaxi-K gene works by creating additional potassium channels (the chemical symbol for potassium is ‘K’) in the smooth muscle cell of the penis. This relaxes the muscle and allows blood flow required for an erection.

“Because this novel therapeutic approach of ion channel therapy works on smooth muscle, it is also promising for overactive bladder disease,” adds Dr. Melman.

Dr. Melman, with George Christ, PhD, developed the process for ion channel therapy at the Albert Einstein College of Medicine, which owns the patents.Montefiore is the academic medical center for Einstein.Einstein has granted licensing rights for the patent to a company called Ion Channel Innovations, which was founded by Dr. Melman, and under whose sponsorship the clinical trials are being conducted.The two study centers in the trials were Mount Sinai Medical Center and NYU Medical Center.


Story Source:

The above story is based on materials provided by Albert Einstein College of Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Albert Einstein College of Medicine. "Gene Therapy For Erectile Dysfunction Shows Promise In Clinical Trial." ScienceDaily. ScienceDaily, 4 December 2006. <www.sciencedaily.com/releases/2006/12/061201180435.htm>.
Albert Einstein College of Medicine. (2006, December 4). Gene Therapy For Erectile Dysfunction Shows Promise In Clinical Trial. ScienceDaily. Retrieved March 29, 2015 from www.sciencedaily.com/releases/2006/12/061201180435.htm
Albert Einstein College of Medicine. "Gene Therapy For Erectile Dysfunction Shows Promise In Clinical Trial." ScienceDaily. www.sciencedaily.com/releases/2006/12/061201180435.htm (accessed March 29, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, March 29, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com
WH Plan to Fight Antibiotic-Resistant Germs

WH Plan to Fight Antibiotic-Resistant Germs

AP (Mar. 27, 2015) The White House on Friday announced a five-year plan to fight the threat posed by antibiotic-resistant bacteria amid fears that once-treatable germs could become deadly. (March 27) Video provided by AP
Powered by NewsLook.com
House Ready to Pass Medicare Doc Bill

House Ready to Pass Medicare Doc Bill

AP (Mar. 26, 2015) In rare bipartisan harmony, congressional leaders pushed a $214 billion bill permanently blocking physician Medicare cuts toward House passage Thursday, moving lawmakers closer to resolving a problem that has plagued them for years. (March 26) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins